Many quinazoline-based anti-cancer agents were granted FDA approval and are in clinical use for cancer management, such as Erlotinib (I) (Figure 1), demonstrating remarkable potency in inhibiting growth factor receptor tyrosine kinases, particularly targeting the EGFR receptor, and featuring quinazoline scaffolds [39]. Here, NTRK1 is linked to cancer.